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Abstract The crystal structure of human recombinant poly-
(ADP-ribose) polymerase (PARP) complexed with a potent in-
hibitor, FR257517, was solved at 3.0 A' resolution. The £uoro-
phenyl part of the inhibitor induces an amazing conformational
change in the active site of PARP by motion of the side chain of
the amino acid, Arg878, which forms the bottom of the active
site. Consequently, a corn-shaped hydrophobic subsite, which
consists of the side chains of Leu769, Ile879, Pro881, and the
methylene chain of Arg878, newly emerges from the well-known
active site.
3 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Poly(ADP-ribose) polymerase (PARP: EC 2.4.2.30), a eu-
karyotic DNA-binding enzyme that participates in cell recov-
ery from DNA damage [1], consists of three functional do-
mains: an N-terminal DNA-binding domain, a C-terminal
catalytic domain (catPARP) and a central automodi¢cation
domain [2]. PARP binds to and is activated by DNA strand
breaks and catalyzes the synthesis of homopolymers of ADP-
ribose from nicotinamide adenine dinucleotide (NADþ) onto
nuclear acceptor proteins. PARP itself is the main protein
acceptor (automodi¢cation), but the enzyme has also been
shown to modify histones, topoisomerases, DNA polymerases
and ligases [3]. The formation of these negatively charged
polymers in the vicinity of the DNA nick is thought to cause
electrostatic repulsion of PARP from the DNA and to facil-
itate recruitment of the base excision repair complex [4]. The
ADP-ribose polymers formed by PARP are cleaved by the
cellular hydrolase poly(ADP-ribose) glycohydrolase. PARP
activation and the rapid synthesis and degradation of ADP
polymers can result in abrupt and profound cellular NADþ
depletion.
Cytotoxic drugs or radiation can induce activation of
PARP, and it has been demonstrated that inhibitors of
PARP can potentiate the DNA-damaging and cytotoxic ef-
fects of chemotherapy and irradiation [5]. Because of the es-
sential function of PARP for cellular repair and survival,
evaluation of the potential of novel, potent PARP inhibitors
for the treatment of cancer in combination with selected cy-
totoxic agents has been sought. These inhibitors have been
designated to mimic the substrate^protein interactions of
NADþ and PARP using the crystal structure of chicken cat-
PARP [6^8]. The active site of PARP is very large and can be
generally classi¢ed into two sites : the acceptor site and the
donor site [6]. The acceptor site is occupied by the ADP moi-
ety of the poly(ADP-ribose) chain. The donor site is occupied
by NADþ, and conveniently classi¢ed into the three subsites
consisting of the nicotinamide-ribose binding site (NI site), the
phosphate binding site (PH site) and the adenine-ribose bind-
ing site (AD site). Known inhibitors bind to the NI site, par-
tially bind to the acceptor site and do not bind to the PH site
and/or AD site. FR257517 (Fig. 1), 2-{3-[4-(4-£uorophenyl)-
3,6-dihydro-1(2H)-pyridinyl]propyl}-8-methyl-4(3H)-quinazo-
linone, a potent inhibitor with an IC50 value of 14 nM, has a
quinazolinone part as a nicotinamide mimic moiety. It is
strongly suggested that the quinazolinone part of the inhibitor
binds to the NI site based upon structural studies up to this
point. The other part of the inhibitor is unique and much
larger than other known inhibitors. Based upon a docking
study, it was assumed that the inhibitor cannot bind to the
acceptor site and/or the AD site without an enforced molec-
0014-5793 / 03 / $30.00 G 2003 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/S0014-5793(03)01362-0
Fig. 1. Chemical structure of FR257517 as a potent inhibitor.
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ular-kink. Thus, it was proposed that FR257517 induces a
structural change to the active site of PARP when the inhib-
itor binds. In order to clarify this hypothesis, we performed an
X-ray analysis of the catalytic domain of human catPARP
complexed with FR257517.
2. Materials and methods
The human catPARP gene corresponding to amino acid numbers
654^1016 was PCR ampli¢ed with a fused protein, glutathione
S-transferase, and a thrombin cleavage site. Luria broth medium
was inoculated with the DH5K Escherichia coli strain containing the
catPARP construct. The cells were harvested by centrifugation. The
suspension was sonicated and cell debris was removed by centrifuga-
tion. The supernatant was puri¢ed with a glutathione Sepharose 4B
(Amersham Pharmacia) incubated after addition of thrombin. The
catPARP protein was concentrated and loaded onto a Superdex 200
HR (Amersham Pharmacia) size-exclusion column. Homogeneous
protein was puri¢ed from this column by isocratic elution with bu¡er:
50 mM Tris^HCl, 150 mM NaCl, 1.5 mM dithiothreitol at pH 7.5.
The inhibitor FR257517 was suspended in the protein solution. The
excess inhibitor was removed by centrifugation before crystallization.
Initial crystals were obtained by the hanging-drop vapor-di¡usion
method using a Crystal Screen kit (Hampton Research). Crystals
were obtained under the No. 39 conditions, which were re¢ned using
the sitting-drop vapor-di¡usion method. The best crystals were ob-
tained using 4 Wl of complex solution, which was mixed with 4 Wl
mother liquor containing 2.1^2.2 M ammonium sulfate, 2%
PEG400, 0.1 M Tris^HCl at pH 8.5. Details of the puri¢cation and
crystallization procedure have been described elsewhere [9].
The crystal was mounted in a nylon loop (Hampton Research) and
cooled to 100 K in a nitrogen gas stream. Di¡raction dataset was
collected at beamline 6B (Photon Factory) using an imaging plate
detector [10]. A wavelength of 1.00 AT and a crystal-to-detector dis-
tance of 573 mm were used. Data integration was performed with
DENZO and scaling and merging were performed using SCALE-
PACK; both programs are from the HKL program package [11].
The structure was solved by the molecular replacement method using
the program AMoRe [12] in the CCP4 program suite. The homology
model calculated based upon chicken catPARP was used as a search
probe. The program Quanta (Accelrys) was used for model building
and CNX (Accelrys) for structure re¢nement. To obtain the confor-
mation of FR257517 in binding to the protein, several di¡erent con-
formations that ¢t the residual density in the electron density omit
map were subjected to geometrical optimization using the CHARMm
force ¢eld and CHARMm minimization module of Quanta (Ac-
celrys). The coordinates have been deposited with the Protein Data
Bank (accession code is 1UK0).
3. Results and discussion
Human catPARP crystallized in space group C2 with unit
cell dimensions of a=179.82 AT , b=53.55 AT , c=92.01 AT , and
L=114.4‡ and with two molecules in the asymmetric unit. The
¢nal model including two inhibitors, one inhibitor per PARP
molecule, has been re¢ned to 3.0 AT . Several amino acids, eight
amino acids from the N-terminus and ¢ve amino acids from
the C-terminus, were omitted from the ¢nal model because of
ambiguous or discontinuous electron density for the corre-
sponding regions. However, both terminal portions are lo-
cated at the opposite side of the active site and are irrelevant
to the enzymatic activity. The R factor and the root mean
square deviation (RMSD) bond lengths and angles reveal a
rather low accuracy, but structural features involving inhibi-
tor^protein interaction can be extracted from the ¢nal model.
Data collection and re¢nement statistics are summarized in
Table 1.
The overall structure of human catPARP is similar to that
of chicken catPARP. Thus, architectures of both catPARP are
conserved with 0.98 AT RMSD for the CK atoms of both
catPARP (Fig. 2). Furthermore, amino acids around the ac-
tive site of both PARP species are perfectly conserved, there-
fore, it is presumed that both PARP species will have a close
resemblance when bound by an inhibitor.
The inhibitor could easily ¢t into the di¡erence electron
density map, and this resulted in the inhibitor bound to the
active site. Thus, the inhibitor mainly binds to the NI and AD
subsites of the donor site, and does not bind the acceptor site
Table 1




Detector system RAXIS-IV (Rigaku)
Wavelength (AT ) 1.00
Space group C2
Cell dimension (AT , ‡) a=179.82, b=53.55, c=92.01, L=114.4




Completeness (%) 95.8 (94.7)
Rmergea (%) 7.5 (24.9)
Re¢nement
Rcrystb/Rfreec (%) 24.0/24.6 (28.3/29.6)
RMSD
Bond lengths (AT ) 0.037
Bond angles (‡) 5.5
Values in parentheses refer to the highest shells: 3.18^3.00 AT resolu-
tion. RMSD, root mean square deviation.
aRmerge =ghklMGIf3IM/ghklMIM.
bRcryst =ghklNFobsM3MFcalcN/ghklMFobsM, summed over only data
(95%) used for re¢nement.
cRfree =ghklNFobsM3MFcalcN/ghklMFobsM, summed over only data (5%)
set aside as the test set.
Fig. 2. A stereo view of ribbon diagram of catPARP. Fragments are indicated by color: chicken catPARP (yellow) and human catPARP (pur-
ple). The inhibitor (blue) is shown in blue stick form.
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at all, although known inhibitors utilize the acceptor site. The
PH site, highly capable of forming hydrogen bonds, is also
unused.
The quinazolinone part of the inhibitor as a nicotinamide
mimic moiety tightly binds to the NI site by three hydrogen
bonds (CNO to Ser904OQ and Gly863NH; NH to Gly863-
CNO) and by a sandwiched hydrophobic interaction consist-
ing of a Z^Z interaction with the phenyl ring of Tyr907 and a
CH^Z interaction with CL of Tyr869. The methylene part of
the inhibitor, positioning at the place corresponding to di-
Fig. 3. Illustrated closed-up views of the active site of catPARP with the same orientation as Fig. 2. a: The active site of PARP can be gener-
ally classi¢ed into two sites: the acceptor site (pink) and the donor site (blue). The acceptor site is occupied by the ADP moiety of the poly-
(ADP-ribose) chain. The donor site is occupied by NADþ, and conveniently classi¢ed into the three subsites consisting of the NI site, the PH
site and the AD site. b: The inhibitor in the new active site. The inhibitor binds to the NI and AD sites, and the acceptor site and the PH site
are unused. The inhibitor also breaks the bottom of the active site wall and produces the hydrophobic corn-shaped subsite.
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phosphate in comparison of chemical structures, does not
participate in direct or indirect binding but passes through
the PH site. In other words, this part is located at an inter-
mediate position between the acceptor and the donor. It is
therefore assumed that the methylene moiety is a spacer to
introduce the pyridine moiety and the £uorophenyl group of
the inhibitor to the AD site. The pyridine moiety of the in-
hibitor interacts by van der Waals contacts with Asn767,
Asp770, Asp796, Asn868 and Ala880 in the AD site. Addi-
tionally, space adjacent to the pyridine moiety remains and a
water molecule is located there. The remaining space occupied
by the water molecule may be primed for binding of a part of
the adenine framework.
It was originally unknown how the £uorophenyl part of the
inhibitor induced the conformational change of catPARP,
although the adenosine site was too narrow for the binding.
It is known that the AD site is at the bottom of the active site
and surrounds the adenine moiety at the terminus of substrate
NADþ (Fig. 3a). Without a conformational change, the £uo-
rophenyl part would cause serious steric-crushes with the pro-
tein. Consequently, the £uorophenyl part of the inhibitor in-
duces an amazing conformational change of the AD site. This
induced ¢tting of the inhibitor enlarges the AD site and
breaks the bottom of the active site (Fig. 3b). Accordingly,
the £uorophenyl group, the terminal part of the inhibitor, can
be seen from the opposite side of the active site. Naturally, no
portion can be seen from the opposite side of the active site in
the known conformation. What is the reason for this large
structural change? The backbone structures around the crit-
ical portion are fully conserved as mentioned, but the side
chain of amino acid Arg878, which forms the bottom of the
AD site of the active site, moves greatly upon inhibitor bind-
ing. Surprisingly, the motion of a single amino acid induces
this large structural change. This also results in generation of
a new hydrophobic subsite with a corn shape, consisting of
the side chains of Leu769, Ile879, Pro881, and the methylene
chain of Arg878.
In summary, we have discovered a novel conformation for
catPARP containing a corn-shaped hydrophobic subsite. This
observation provides a new concept in inhibitor design using
the emerged hydrophobic site, which is located on the oppo-
site side of the active site and therefore has been unused in
inhibitor design so far.
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